RedHill Biopharma

RedHill Biopharma Ltd. develops medicines for gastrointestinal and infectious diseases. It operates through Commercial Operations, and the Research and Development segments. The Commercial Operations segment covers all areas relating to the commercial sales and is being performed by the subsidiary in the U.S. The Research and Development segment includes the study and licensing of therapeutic candidates. Its products include Talicia, Movantik, and Aemcolo. The company was founded by Dror Ben-Asher and Ori Shilo on August 3, 2009 and is headquartered in Tel Aviv, Israel.

Earnings data Q4 2019

Earnings data Q1 2020

Earnings data Q2 2020

Earnings data Q3 2020

Earnings data Q4 2020

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q4 2023

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

TEL AVIV, Israel and RALEIGH, N.C., Jan. 29, 2021 /PRNewswire/ -- RedHill Biopharma Ltd. (Nasdaq: RDHL) ("RedHill" or the "Company"), a specialty biopharmaceutical company, today announced that the independent Data Safety Monitoring Board (DSMB) for the global Phase 2/3 study of...

RedHill Biopharma Announces Positive DSMB Futility Review for Phase 2/3 COVID-19 Study of Opaganib

Atea Pharmaceuticals

This could be a key year for these companies' treatment candidates.

These 2 Coronavirus Stocks Could Soar in the First Half of 2021

TEL AVIV, Israel and RALEIGH, N.C., Jan. 14, 2021 /PRNewswire/ -- RedHill Biopharma Ltd. (Nasdaq: RDHL) ("RedHill" or the "Company"), a specialty biopharmaceutical company, today announced the closing of its previously announced underwritten offering of 3,188,776 American Depositary...

RedHill Biopharma Announces Closing of $25 Million Bought Deal Offering

The drugmaker more than doubled the size of its planned public stock offering.

Why RedHill Biopharma Stock Is Tanking Today

TEL AVIV, Israel and RALEIGH, N.C., Jan. 12, 2021 /PRNewswire/ -- RedHill Biopharma Ltd. (Nasdaq: RDHL) ("RedHill" or the "Company"), a specialty biopharmaceutical company, today announced that due to demand, the underwriter has agreed to increase the size of the previously announced...

RedHill Biopharma Increases Previously Announced Bought Deal to $25 Million

TEL AVIV, Israel and RALEIGH, N.C., Jan. 11, 2021 /PRNewswire/ -- RedHill Biopharma Ltd. (Nasdaq: RDHL) ("RedHill" or the "Company"), a specialty biopharmaceutical company, today announced that it has entered into an underwriting agreement with H.C. Wainwright & Co., LLC under which the...

RedHill Biopharma Announces $10 Million Bought Deal Offering

RedHill (RDHL) gets Fast Track status from the FDA for the treatment of nontuberculous mycobacteria (NTM) disease.

RedHill's (RDHL) RHB-204 Gets FDA Fast Track Designation

RedHill's (RDHL) opaganib achieves greater improvement in reducing oxygen requirement compared to placebo in a phase II study evaluating it in patients hospitalized with COVID-19 pneumonia.

RedHill (RDHL) COVID-19 Drug Shows Promise in Mid-Stage Study

TEL AVIV, Israel and RALEIGH, N.C., Dec. 31, 2020 /PRNewswire/ -- RedHill Biopharma Ltd. (Nasdaq: RDHL) ("RedHill" or the "Company"), a specialty biopharmaceutical company, today announced that preliminary top-line data from its U.S. Phase 2 study with orally-administered opaganib...

RedHill Biopharma Announces Positive Top-Line Safety and Efficacy Data from Phase 2 COVID-19 Study of Opaganib

Investors need to pay close attention to RedHill Biopharma (RDHL) stock based on the movements in the options market lately.

Is the Options Market Predicting a Spike in RedHill Biopharma (RDHL) Stock?

RedHill has a stable line of approved, marketed and pipeline products. Its cash balance is a little low.

RedHill: A Slow And Steady Climb Towards Biopharma Success

The latest 13F reporting period has come and gone, and Insider Monkey is again at the forefront when it comes to making use of this gold mine of data. We at Insider Monkey have plowed through 817 13F filings that hedge funds and well-known value investors are required to file by the SEC. The 13F filings show the funds' and investors' portfolio positions as of September 30th, about a month before the elections. In this article we look at what those investors think of RedHill Biopharma Ltd (NASDAQ:RDHL).

Do Hedge Funds Love RedHill Biopharma Ltd (RDHL)?

RedHill (RDHL) expands its manufacturing capacity to support the potential emergency use applications to be filed for opaganib to address severe COVID-19 pneumonia in the United States.

RedHill (RDHL) Expands Opaganib Manufacturing Capacity in US

TEL AVIV, Israel and RALEIGH, N.C., Nov. 25, 2020 /PRNewswire/ -- RedHill Biopharma Ltd. (Nasdaq: RDHL) ("RedHill" or the "Company"), a specialty biopharmaceutical company, today announced partnerships with two leading, U.S.-based manufacturers for large-scale manufacturing of opaganib[1]....

RedHill Biopharma Expands U.S.-Based Manufacturing Capacity of Opaganib for COVID-19

TEL AVIV, Israel and RALEIGH, N.C., Nov. 20, 2020 /PRNewswire/ -- RedHill Biopharma Ltd. (Nasdaq: RDHL) ("RedHill" or "the Company"), a specialty biopharmaceutical company, today announced that it has initiated its Phase 3 study to evaluate the safety and efficacy of RHB-204 as a...

RedHill Biopharma Initiates Phase 3 Study of RHB-204 for First-Line Treatment of NTM Disease

The FDA clears RedHill's (RDHL) IND filing for a phase II/III study on its second coronavirus candidate RHB-107 to treat patients with symptomatic COVID-19 who do not require hospitalization.

RedHill (RDHL) to Begin Study on Second Coronavirus Candidate

Redhill (RDHL) completes enrollment in the phase II study on opaganib in patients hospitalized with severe COVID-19 pneumonia.

RedHill (RDHL) Closes Enrollment for Phase II Coronavirus Study

TEL AVIV, Israel and RALEIGH, N.C., Nov. 17, 2020 /PRNewswire/ -- RedHill Biopharma Ltd. (Nasdaq: RDHL) ("RedHill" or the "Company"), a specialty biopharmaceutical company, today announced that the U.S. Food and Drug Administration (FDA) has cleared the Company's Investigational New Drug...

RedHill Biopharma's Second COVID-19 Candidate, RHB-107, Cleared by FDA for Phase 2/3 Study in Symptomatic COVID-19 Disease

TEL AVIV, Israel and RALEIGH, NC, Nov. 16, 2020 /PRNewswire/ -- RedHill Biopharma Ltd. (Nasdaq: RDHL) ("RedHill" or the "Company"), a specialty biopharmaceutical company, today announced that the U.S. Phase 2 study with opaganib (Yeliva®, ABC294640)[1] in patients hospitalized with severe...

RedHill Biopharma Completes Enrollment for COVID-19 U.S. Phase 2 Study with Opaganib - Data Expected in the Coming Weeks

RedHill Biopharma Ltd. (RDHL) CEO Dror Ben-Asher on Q3 2020 Results - Earnings Call Transcript

Shares of Redhill Biopharma (NASDAQ:RDHL) remained unaffected after the company reported Q3 results. Quarterly Results Earnings per share fell 66.67% year over year to ($0.05), which beat the estimate of ($0.16).

Recap: Redhill Biopharma Q3 Earnings

Q3/2020 net revenues of approximately $21 million , with gross profit of $10.6 million , or approximately 51% , up from $6.7 million and approximately 32% in Q2/2020 -- Strong growth for Talicia ® with approximately 300 % quarter- over -quarter prescription growth and rapid expansion of the prescriber base ; Talicia achieved national coverage for 167 million lives since launch, with additional coverage expected -- T wo consecutive quarters of Movantik ® prescription ( TRx ) growth , reversing the trend of prescription decline prior to RedHill acquisition -- Opaganib's COVID-19 global Phase 2/3 study advancing rapidly with nearly 50% of patients enrolled and U.S. Phase 2 stud y over 90% enrolled ; Initiated manufacturing ramp-up in preparation for potential e mergency u se applications as early as Q1/2021 -- Commencing Phase 3 study with RHB-204 for first-line treatment of pulmonary NTM infection s -- Cash balance of approximately $ 51 million as of September 30 , 2020 -- Management to host webcast today, at 8:30 a.m. EST

RedHill Biopharma Provides Q3/2020 Results and Highlights, Including 300% Talicia Prescription Growth

Notice of Allowance received for combination of RedHill's novel orally-administered investigational drugs, opaganib and RHB-107, for treatment of solid tumor cancers; patent expected to extend IP protection until 2036

RedHill Biopharma Receives U.S. Patent Allowance Covering Opaganib and RHB-107 Combination

  H. pylori e radication rates with clarithromycin-based triple therapy were found to be predictably low in the Phase 3 trial , with antibiotic resistance a contributing factor . D espite declining efficacy, physicians are still prescribing these regimens counter to ACG guidelines , which advocat e for us ing first-line regimens that provid e the highest likelihood of eradication success -- Talicia 's efficacy in the Phase 3 study was unaffected by patient body mass index ( BMI ) , while published data suggest that BMI may be associated with the failure of clarithromycin-based H. pylori treatments , further supporting the use of Talicia as a first-line therapy i n all populations -- Talicia is the first and only FDA-approved rifabutin-based therapy for the treatment of H. pylori infection , designed as a first-line option to address the high and growing resistance of H. pylori to commonly used antibiotics

RedHill Biopharma Presents New Data from Talicia®'s Phase 3 Studies at ACG 2020 Focused on Achieving Successful First-Line Treatment in H. pylori Eradication

RedHill (RDHL) gets Orphan Drug status from the FDA for the treatment of nontuberculous mycobacteria (NTM) disease.

News for RedHill Biopharma Stock (RDHL)